What did FDA withdraw about teen tanning beds?

FDA withdrew a proposed ban on teen tanning beds

The U.S. Food and Drug Administration has withdrawn a proposed rule that would have barred Americans under age 18 from using tanning beds.

The decision is significant because it would have addressed a long-running public health concern: ultraviolet exposure from indoor tanning is linked to increased risk of skin cancer. A rule limiting access for minors would have shifted tanning-bed regulation toward prevention by reducing exposure during high-risk adolescent and early adult years.

With the proposal withdrawn, the path for a federal restriction for under-18s is no longer set by that specific FDA rule. Instead, the policy landscape will depend on what replaces it—whether there are new proposals, changes at the state level, or continued reliance on existing frameworks.

Why this matters: - Public health prevention: Reducing tanning-bed access for teens is a direct strategy to lower future skin cancer risk. - Regulatory uncertainty: Withdrawal creates a gap between advocates’ goal of stronger federal limits and the current regulatory status. - State variability: In the absence of a uniform federal ban, access restrictions may continue to vary widely across states.

The report provides limited detail beyond the fact that the FDA withdrew the proposal, so it’s not clear what specifically drove the withdrawal or what regulatory actions may follow. For now, the practical outcome is that the proposed under-18 tanning-bed ban is not moving forward in that form.